Clearside Biomedical, Inc. Forecast, price target & analysts
Clearside Biomedical, Inc. Target price 2025 - Analyst rating & recommendation
Clearside Biomedical, Inc. Classifications & Recommendation:
Clearside Biomedical, Inc. Price Target
| Target Price | $5.71 |
| Price | $0.86 |
| Potential |
563.68%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Clearside Biomedical, Inc. 2026 .
The average Clearside Biomedical, Inc. target price is $5.71.
This is
563.68%
register free of charge
$8.00
829.15%
register free of charge
$4.00
364.58%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Clearside Biomedical, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clearside Biomedical, Inc. stock has an average upside potential 2026 of
563.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.66 | 0.82 |
| 79.83% | 50.46% | |
| EBITDA Margin | -1,726.51% | -4,169.60% |
| 473.41% | 141.51% | |
| Net Margin | -2,168.23% | -3,910.81% |
| 339.66% | 80.37% |
7 Analysts have issued a sales forecast Clearside Biomedical, Inc. 2025 . The average Clearside Biomedical, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Clearside Biomedical, Inc. 2025 . The average Clearside Biomedical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Clearside Biomedical, Inc. 2025 . The average Clearside Biomedical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.47 | -0.42 |
| 11.32% | 10.64% | |
| P/E | negative | |
| EV/Sales | 120.22 |
1 Analysts have issued a Clearside Biomedical, Inc. forecast for earnings per share. The average Clearside Biomedical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Clearside Biomedical, Inc....
Current Clearside Biomedical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
